Serious safety events in rituximab‐treated multiple sclerosis and related disorders

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients

(2020) Peter Alping et al.   ANNALS OF NEUROLOGY

Association between suicide and multiple sclerosis: An updated meta-analysis

(2019) Qiuyan Shen et al.   Multiple Sclerosis and Related Disorders

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

(2018) Mathias Granqvist et al.   JAMA Neurology

Severe neutropenia after rituximab-treatment of multiple sclerosis

(2018) Eero Rissanen et al.   Multiple Sclerosis and Related Disorders

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study

(2018) Bassem I. Yamout et al.   Journal of Immunology Research

Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience

(2018) Emanuele D'Amico et al.   Multiple Sclerosis and Related Disorders

Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review

(2018) Sareh Shahmohammadi et al.   Multiple Sclerosis and Related Disorders

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders

(2016) Valentina Damato et al.   JAMA Neurology

Multiple sclerosis increases the risk of venous thromboembolism: a nationwide cohort analysis

(2015) Wei-Sheng Chung et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)

(2015) P. S. Rommer et al.   Journal of Neuroimmune Pharmacology

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

(2015) Hélène Zéphir et al.   JOURNAL OF NEUROLOGY

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

(2015) M Radaelli et al.   Multiple Sclerosis Journal

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

(2015) M Radaelli et al.   Multiple Sclerosis Journal

The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

(2014) Stephen L Hauser   Multiple Sclerosis Journal

B cells in MS and NMO: pathogenesis and therapy

(2014) Markus Krumbholz et al.   Seminars in Immunopathology

Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica

(2013) Annika Plate et al.   Multiple Sclerosis and Related Disorders

Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica

(2013) Jennifer Graves et al.   Multiple Sclerosis and Related Disorders

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

(2012) Carla Casulo et al.   Clinical Lymphoma Myeloma & Leukemia

Multiple Sclerosis and Risk of Venous Thromboembolism: A Population-Based Cohort Study

(2012) Steffen Christensen et al.   NEUROEPIDEMIOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE